What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings?

Zymeworks Inc. (NASDAQ:ZYME) – Equities research analysts at HC Wainwright cut their Q2 2026 EPS estimates for Zymeworks in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.58) per share for the quarter, down from their prior estimate of ($0.29). HC Wainwright has a “Buy” rating and a $51.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at ($0.54) EPS and FY2026 earnings at $0.36 EPS.

A number of other brokerages also recently commented on ZYME. Truist Financial raised their target price on shares of Zymeworks from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Citigroup reiterated a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Finally, Wells Fargo & Company upped their target price on Zymeworks from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.89.

Zymeworks Price Performance

Zymeworks stock opened at $23.13 on Friday. Zymeworks has a 12 month low of $11.51 and a 12 month high of $29.75. The stock’s 50-day moving average is $24.02 and its 200-day moving average is $24.46. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -16.88 and a beta of 1.15.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). Zymeworks had a negative net margin of 126.92% and a negative return on equity of 37.97%. The company had revenue of $4.59 million during the quarter, compared to analyst estimates of $3.81 million. During the same quarter last year, the business earned $0.03 EPS. The firm’s revenue for the quarter was down 90.6% compared to the same quarter last year.

Institutional Investors Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Zymeworks by 86.0% in the 1st quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after buying an additional 22,411 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after acquiring an additional 1,427 shares during the last quarter. Jane Street Group LLC increased its position in shares of Zymeworks by 487.0% during the first quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock worth $1,617,000 after acquiring an additional 112,636 shares during the last quarter. Creative Planning lifted its stake in shares of Zymeworks by 114.8% in the second quarter. Creative Planning now owns 25,389 shares of the company’s stock worth $319,000 after acquiring an additional 13,567 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Zymeworks by 1,050.0% in the second quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock worth $5,543,000 after acquiring an additional 403,281 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks declared that its Board of Directors has approved a share repurchase plan on Thursday, May 14th that allows the company to repurchase $125.00 million in shares. This repurchase authorization allows the company to reacquire up to 7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.